Yichenyun Health Raises ￥10M in Series A Round

According to VCBeat, Guangzhou Yichenyun Health Technology Co., Ltd ("Yichenyun Health") recently completed a Series A financing of tens of millions, led by Guangzhou-based Redhill Capital, with participation from Guangzhou Chuangyu Mingchen Equity Investment and Tsingyuan Ventures. The funds raised will be mainly used for factory construction, clinical trials and product declaration.

Yichenyun Health is headquartered in Guangzhou, China, and has an R&D center and subsidiary in Silicon Valley. The company is committed to the prevention of nosocomial infection with innovative technology. It has propriety R&D technology and a number of global patents, with products selling to the world, aimed at serving more patients and caring for human health.

The harm of nosocomial infection is more and more serious, but there are few related products. To this end, Yichenyun Health focuses on the prevention and control of nosocomial infection and has first developed the catheter-related bloodstream infection (CRBSI) prevention and control device and the umbilical cord care device in newborns.

CRBSI prevention and control devices are used to prevent possible infections during catheter insertion in cancer chemotherapy, intensive care, hemodialysis of renal failure, parenteral nutrition, and surgery. At present, cancer chemotherapy is the usual application scenario, with a large number of cancer patients. Long-term catheter insertion is required during chemotherapy, which makes the high possibility of CRBSI.

Compared to other products that take 15-20 minutes to replace each time, Yichenyun Health 's device of CRBSI can be installed in 5 minutes. In addition, patients can be trained to use the device directly at home, which will greatly improve efficiency. It is also worth mentioning that the device is also applicable to children, infants and allergic people.

Headquartered in Guangzhou, Redhill Capital is a venture capital firm specializing in early-stage investment. It primarily invests in the medical industry. The company has nearly 20 years of experience and has invested in dozens of medical enterprises, many of which have become the leading enterprises in the industry.

Tsingyuan Ventures is a technology-focused venture fund that invests in seed to A-round startups in the United States. It is a successor fund to the TEEC Angel Fund. The company was founded in 2017 and is headquartered in Los Altos, California.